The addition of nivolumab to chemotherapy demonstrated continuing improved survival compared with chemotherapy alone after 24 months of follow-up.
All articles by Andrea S. Blevins Primeau, PhD, MBA
Residual pathologic disease often remains after neoadjuvant chemotherapy and resection in patients with esophageal or GEJ cancers, and these patients have a high risk of recurrence.
The American Society of Clinical Oncology (ASCO) highlights the past year’s oncologic advances and identifies important areas for future research in its 2021.
COBRA investigators will evaluate circulating tumor DNA (ctDNA) as a biomarker for adjuvant chemotherapy benefit in 1408 patients with resected, stable stage IIA colon cancer.
Combination tivozanib and durvalumab was found to be well-tolerated in patients with advanced, treatment-naïve hepatocellular carcinoma (HCC).
Investigators evaluated the prevalence and severity of gastrointestinal symptoms in patients with COVID-19 and cancer who were hospitalized during the study period.
Antibiotic use prior to ICI treatment may reduce ICI efficacy and result in worse survival outcomes among patients with cancer, in a retrospective study.
Preliminary data suggest that neoadjuvant treatment of resected pancreatic cancer with urelumab plus nivolumab and GVAX was well tolerated and showed some antitumor activity in a small study.
The survival-inferred fragility index of phase 3 trials for immune checkpoint inhibitors suggests that, despite statistical significance, survival data do not show a robust clinical benefit.